Research progress of drugs for cancer immunotherapy based on CCL2/CCR2 signaling axis1

VernacularTitle:基于CCL2/CCR2信号轴的肿瘤免疫治疗药物的研究进展
Author: Zhenzhen CUI ; Yifan ZHAO ; Yu SUN
Publication Type:Journal Article
Keywords: CCL2 / CCR2 / cancer immunotherapy / tumor microenvironment / immunosuppressive cells
From: Journal of China Pharmaceutical University 2024;55(1):36-44
CountryChina
Language:Chinese
Abstract: C-C motif chemokine ligand 2 (CCL2) and its receptor CCR2 are closely related to tumorigenesis and tumor progression. The CCL2/CCR2 signaling axis promotes tumor progression through multiple mechanisms: CCL2 binds to CCR2 on the surface of tumor cells, and thus promotes tumor growth/survival and metastasis; more importantly, CCL2 recruits a variety of immunosuppressive cells to aggregate in the tumor microenvironment, and inhibits the function and activity of immune cells, promoting tumor progression. The article reviews the CCL2/CCR2 signaling axis and its role in tumors and tumor microenvironment, with particular focus on the advances in clinical research on drugs targeting CCL2/CCR2 signaling axis, in order to gain an in-depth and overall understanding of the mechanism of action of CCL2/CCR2 axis in tumor progression and develop more effective anti-tumor immunotherapeutic agents.